Vitor-Belfort - MMAWEEKLYOfficially, UFC middleweight Michael Bisping has lost two of his last three tilts with stumbles against Chael Sonnen and most recently Vitor Belfort. However, from Alan Belcher’s perspective, his UFC 159 foe hasn’t come up short in the cage since being outpointed by Wanderlei Silva three years ago.

In a recent blog for Yahoo Sports, Belcher made it clear he feels fighters who use testosterone replacement therapy are cheaters and, as a result, he doesn’t count any of their successes while subscribing to the controversial practice (as both Belfort/Sonnen do).

“Bisping didn’t lose to Vitor Belfort in January,” wrote Belcher. “When someone cheats with substances, like Belfort has done, it doesn’t count as a win. Belfort hasn’t proved he can win a big fight without taking steroids or TRT, so I think when I KO Bisping I should get all the recognition for being the first guy to do so since Dan Henderson did at UFC 100.”

Of course, Henderson is also a TRT user, meaning Belcher could actually be the first person to ever finish Bisping using his logic. Regardless of what he himself thinks, Belcher is certain “The Count” still feels like a loser after being blasted by Belfort and as such he expects a dangerous adversary in the Octagon in April 27.

“I know he’s going to be very motivated after his last fight. He was embarrassed to lose another #1 contender fight last time and will want to win this fight bad,” explained Belcher. “Only, I’m as good as he is in all areas but with better submissions and a lot more power in my strikes. I can walk through his best shots, but one of mine will knock him out. All his smack talk won’t change that.”

The bout between Belcher-Bisping will serve as the evening’s co-headliner at UFC 159. The 18-7 Belcher had a four-fight winning streak snapped in December due to a decision loss against Yushin Okami but has finished sixteen of the opponents he’s beaten. Comparably, Bisping is 23-5 with eighteen stoppages and owns past victories over the likes of Yoshihiro Akiyama, Chris Leben, and Brian Stann.